President and CEO
Kathryn Hayashi is President and CEO of TRIUMF Innovations, the business interface and commercialization arm, connecting TRIUMF, Canada's particle accelerator centre, to the private sector via industry partnerships, licensing, and company creation.
Ms. Hayashi is a Chartered Professional Accountant with more than 25 years of operational and strategic planning, finance and governance experience in not-for-profit organizations, public and private companies, start-ups, and commercialization accelerators/incubators.
Prior to TRIUMF Innovations, she was the Founding Chief Financial Officer of The Centre for Drug Research and Development, Canada’s national drug development and commercialization engine. In addition to her work establishing CDRD as a leader in pre-clinical translational research and commercialization, Ms. Hayashi presides as a Director and Audit Committee Chair of the Center for Commercialization and Cancer Immunotherapy at the Hôpital Maisonneuve-Rosemont, as well as the Discovery Parks technology incubator, and has served on the boards of several spinoff companies.
David Asgeirsson, Ph.D.
Director, Business Development - Physical Sciences
David works at the interface of academic research and industrial applications. He is active in hard tech startups, technology transfer, university-industry liaison, research partnerships, and industrial R&D and innovation.
For more than five years, David carried out technology assessments and managed commercialization projects for MaRS Innovation in areas such as biomedical signal processing, high speed analog electronics, high power electronics, electronic materials and solar energy. He sought out the most promising inventions, worked with patent agents to secure the IP and with inventors to continue prototyping and testing, obtained grant funding from government agencies, and engaged industry partners for partnerships, co-development and licensing.
He has wide knowledge and experience in physical sciences, information technology (both hardware and software), and extensive experience communicating technical and scientific information to mixed audiences, ranging from academic conferences to corporate board rooms.
Director, Intellectual Property and Legal Affairs
Gina is the Director of Intellectual Property and Legal Affairs at TRIUMF Innovations. In this capacity, Gina works with potential and current TRIUMF spin off companies on IP and contracts. She is a former patent examiner at the US Patent and Trademark Office and a registered US Patent Attorney who is licensed to practice law in both New York State and British Columbia. Gina has practised intellectual property law for more than 10 years. Her background is in mechanical and civil engineering and technology consulting.
Director, Business Development - Life Sciences
Kevin’s experience and skill set is finding partners and creating partnership arrangements for commercialization of early stage life science technologies between and among academic institutions, government Network Centers of Excellence, small and medium sized companies, as well as multinational companies. A business development consultant since 2004, Kevin has participated in commercialization of 13 products and provided business development services for 24 clients. He is familiar with negotiating, implementing, and managing many aspects of commercialization including, technology in-licensing and out-licensing, technology development partnerships, creating start-up companies, planning and implementing product launches, and financing presentations. At TRIUMF Innovations Kevin’s focus is working with TRIUMF scientists, engineers, physicists and their collaborators to improve their connections with the business world for the purpose of commercializing their innovations and inventions for applications in the life sciences.
Michael Trinczek, Ph.D.
PIF/NIF Irradiation Manager, TRIUMF
Michael Trinczek received his Ph.D. in experimental nuclear physics from Simon Fraser University, Canada in 2001 after completing a B.Sc. (Honours) in chemistry. After a post-doctoral research term at the Max-Planck-Institute for Nuclear Physics in Heidelberg, Germany, he returned to TRIUMF where he has held various roles in facilities and operations. In 2010, Michael assumed responsibility for TRIUMF’s Irradiation Facilities and helps support the Proton Therapy Facility for the treatment of ocular melanoma. Since then, he has been involved in the radiation-effects community and was part of the research collaboration that won the Outstanding Paper Award at the IEEE Nuclear and Space Radiation Effects Conferences two years in a row in 2014 and 2015. He has helped grow the TRIUMF irradiation business over the past few years, using targeted facility upgrades and customer outreach, increasing commercial revenue by more than 400% while hosting over 70 company visits in 2016. In addition to his research activities, Michael sits on the TRIUMF Innovations and Industrial Partnerships panel that is responsible for knowledge and technology transfer activities between TRIUMF and other organizations, is the secretary for the TRIUMF Life Sciences Projects Evaluation Committee, and is a member of both the IEEE and the Canadian Association of Physicists.